Viewing Study NCT06926205


Ignite Creation Date: 2025-12-25 @ 3:30 AM
Ignite Modification Date: 2026-02-28 @ 12:18 AM
Study NCT ID: NCT06926205
Status: RECRUITING
Last Update Posted: 2025-04-13
First Post: 2025-03-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL
Sponsor: GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module